Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mitapivat Sulfate

FDA-approved product (tablet, oral), marketed as Aqvesme, Pyrukynd.

Registered studies
19
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Mitapivat Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anemia
  • Familial hemolytic anemia
  • Genetic disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other hematological agents
FDA pharmacologic class
Pyruvate Kinase Activator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

19registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Mitapivat Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mitapivat Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants

    NCT04565678 · start 2020-09-21

    Registered record
    Registry ID
    NCT04565678
    Conditions
    Healthy Volunteers
    Interventions
    Mitapivat tablets; Mitapivat coated granules
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-09-21
    Completion
    2020-12-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionMitapivat tablets; Mitapivat coated granules
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants

    NCT04472832 · start 2020-06-17

    Registered record
    Registry ID
    NCT04472832
    Conditions
    Healthy Volunteers
    Interventions
    Placebo for Treatment A; Mitapivat 100 mg; Placebo for Treatment B; Mitapivat 300 mg; Placebo for Treatment C
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-06-17
    Completion
    2020-11-23
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionPlacebo for Treatment A; Mitapivat 100 mg; Placebo for Treatment B; Mitapivat 300 mg +1 more
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants

    NCT03991312 · start 2019-06-20

    Registered record
    Registry ID
    NCT03991312
    Conditions
    Healthy Volunteers
    Interventions
    itraconazole; rifampin; mitapivat sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-06-20
    Completion
    2019-09-10
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Interventionitraconazole; rifampin; mitapivat sulfate
    PhasePhase 1
    Registry statusCompleted

  • Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

    NCT03853798 · start 2019-03-21

    Registered record
    Registry ID
    NCT03853798
    Conditions
    Pyruvate Kinase Deficiency
    Interventions
    Mitapivat
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-03-21
    Completion
    2024-07-03
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPyruvate Kinase Deficiency
    InterventionMitapivat
    PhasePhase 3
    Registry statusCompleted